Abstract
The outbreak of COVID19 has been declared a global pandemic by WHO which started in Wuhan last November and now has spread to more than 200 countries with 4.5 million cases and a death toll of more than 300 thousand. In response, many countries have implemented lock down to ensure social distancing and started rigorously quarantining the infected subjects. Here we utilized the infection dynamics available from WHO and quantitatively calibrated the confirmed, recovered, and dead populations from 23 different countries. The chosen countries chosen are in three stages of infection 1. Where the first wave of infection is significantly diminished 2. Infection peak is reached but daily infection still persists significantly 3. The infection peak is not yet reached. The model successfully captured the daily trajectories of countries with both early and late phase of infection and determined incubation time, transmission rate, quarantine and recovery rates. Our analysis shows, the reduction in the estimated reproduction number with time is significantly correlated to the testing rate and medical facility of a country. Further, our model identifies that an increase in quarantine rate through more testing could be the most potent strategy to substantially reduce the undetected infection, accelerate the time to infection peak and facilitate faster recovery of a nation from the first infection wave, which could perhaps have direct social and economic implications. Our model also shows, that post lockdown infection spread towards a much larger second wave can be controlled via rigorous increase in the quarantine rates which could be tailored in a country specific manner; for instance, our simulations suggest that USA or Spain would require a 10 fold more increase in quarantine rates compared to India to control the second wave post lockdown. Our data driven modeling and analysis of the trajectories from multiple countries thus pave a way to understand the infection dynamics during and post lockdown phases in various countries and it can help strategize the testing and quarantine processes and influence the spread of the disease in future.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding agencies supported the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Details of the model simulation and fitting are available upon reasonable request.